Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Schering-Plough, Novartis expand an asthma pact

August 21, 2006 | A version of this story appeared in Volume 84, Issue 34

Schering-Plough and Novartis have extended their collaboration on combination therapies for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The firms will combine mometasone, the corticosteroid active ingredient in Schering-Plough's Asmanex, and indacaterol, a β2-agonist being developed by Novartis, into a once-daily inhalation therapy. The companies will share development costs and copromote a combination therapy worldwide. The two currently have another combination therapy for asthma and COPD, composed of Asmanex and Novartis' Foradil, in Phase III clinical trials.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.